CRIS - Strong Double BottomsRecurring Double Bottom patterns are evident
Once price completes its current double bottom 1.70 is a good target for price to aim for
CRIS trade ideas
Cris Although it had nic rip off support of a larger pattern with another test of the mid term downward resiatnce I am looking to potentially scoop some up. I really want to see how we react at this 7.60$ level holding as support. Might be worth a buy attempt. Targets of 10$+ howver the Key breakout level isn’t until we did suppprt above 8.05$. Therefor that’s the safest area to lonf from
CRIS Primed for a reversalThe technicals are in favor for a bullish run. with a major gap to fill near 11.94. I think we see a positive run in the coming days
Big Winners For Monday 6/12/21 According To My AIThis is my top 10 estimates for the highs of the day on Monday (6/12/2021) according to my AI program and for those users that have been following my ai idea updates, I have improved the ai quite a bit to provide much more accurate results and I have implemented a scoring system that ranges from +30 to -30 and this is essentially the AI confidence that the estimate will be reached so +30 is the highest confidence and -30 is the lowest confidence.
Symbol | Last Close | Estimated High | Est% | Score
CRIS | 8.01 | 10.10 | 26.11 | 25
WISH | 10.00 | 12.07 | 20.68 | 0
VIXY | 25.23 | 30.27 | 19.99 | 0
CAN | 8.72 | 10.29 | 17.97 | 15
TAL | 29.23 | 34.30 | 17.36 | 25
PROG | 3.21 | 3.70 | 15.39 | 10
SPCE | 35.10 | 39.40 | 12.24 | -25
RUN | 44.96 | 50.39 | 12.08 | -20
ESTC | 136.67 | 153.05 | 11.98 | -20
CAKE | 56.08 | 61.73 | 10.07 | 0
I have made CRIS the chart since it is at the top of my list and the indicators because they are my favorites. I will update this idea with the actual highs of the day of course. This is an ongoing series for me so make sure to share your opinions, positive or negative. Thanks for following!
CURIS STOCKIf we hold, we have a double bottom in play. This could lead to filling the gap that has occurred. Look for institutions to treat this as the Demand zone. The recent sell off was the supply zone.
CRIS - Daily chart analysisNot much to say about this. Prime example of what happens when top resistance breaks.
NO POSITION.
You get the idea. Touching a past support level and just touching the regression line. I'm kind of at the outlook of CRIS beginning to climb.
positive prelim data from a Phase 1 study-leukemia treatmentCuris Announces Positive Preliminary Data from Ongoing Phase 1 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Key findings include:
- Marrow blast reductions observed in all evaluable patients (6 patients).
- 6 of 7 patients enrolled remain on study.
- Patients enrolled experienced a median of 3 prior lines of treatment (range 1-4).
- Two patients experienced a marrow complete response, one with blast count going from 23% pretreatment to 1% on treatment, and the other going from 11% pretreatment to 2% on treatment.
- No DLTs observed in 7 DLT-evaluable patients in the 200 mg BID and 300 mg BID cohorts.
- Enrollment has begun in the 400 mg BID cohort.
Curis said its CA-4948 monotherapy in adult patients was well tolerated, has demonstrated signs of biologic activity in the ongoing study and is capable of achieving "relevant levels of drug exposure."
finance.yahoo.com
BREAKOUT CUP WITH HANDLE BUY CRIS ABOUT 9.50$Curis Announces Positive Preliminary Data from Ongoing Phase 1 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes
1% CAPITAL
Curis (CRIS) possible leukemia cure breakthroughCuris skyrockets 448% after encouraging phase 1 data for leukemia treatment! BE CAREFUL here, this is a speculative play. I got a couple batches of shares. Do your own due diligence, your risk is 100% your responsibility. You win some or you learn some. Consider being charitable with some of your profit to help humankind. Small incremental steps work : If you double a penny for a month it = $5,368,709. Good luck and happy trading friends...
*3x lucky 7s of trading*
7pt Trading compass:
Price action, entry/exit
Volume average/direction
Trend, patterns, momentum
Newsworthy current events
Revenue
Earnings
Balance sheet
7 Common mistakes:
+5% portfolio trades, risk management
Beware of analysts motives
Emotions & Opinions
FOMO : bad timing
Lack of planning & discipline
Forgetting restraint
Obdurate repetitive errors
7 Important tools:
Trading View app!, Brokerage UI
Accurate indicators & settings
Wide screen monitor/s
Trading log (pencil & graph paper)
Big organized desk
Reading books, playing chess
Sorted watch-list
Checkout my indicators:
Fibonacci VIP - volume
Fibonacci MA7 - price
pi RSI - trend momentum
www.tradingview.com
Curis Announces Positive Preliminary Data from Ongoing Phase 1 SCRIS: Curis, Inc.
2020-12-08 07:00:00
Curis Announces Positive Preliminary Data from Ongoing Phase 1 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes
$CRIS longDo your research on $TRIL and $FTSY. You'll see why I'm excited to invest in this company.
CURIS is base forming again?NASDAQ:CRIS
DISCLOSURE: II've been a long follower of CURIS since two years ago and experienced an abysmal loss last year because I got married with this stock. LOL.
Key fundamentals:
$17.5 million shares offering at $1.24 on June 12, 2020.
FDA clearance of IND application for CI-8993 on June 10, 2020 and the stock sky rocketed from .86c to $3.86 range on June 10, 2020.
Stock moved from .86c to $1.22 without any news or materialized events on June 9, 2020.
Curis reports that they only have $12,538 million left on May 12, 2020 with an average cash burn rate of around $8 million.
Aspire capital made an initial investment of $3 million dollars on Feb. 27, 2020. Promising up to $27M investment "based on the market price at the time of each sale, subject to certain limits"
Catalyst:
There is only ONE catalyst for CURIS this year. The "CA-4948 in patients with AML/MDS and certain spliceosome mutation" which we have NO indication which quarter this year. Be mindful that the SP tanked on December because the data was, so askew and confusing which the market did not took it very well. What made it worst is that Dentzer made a very strong point months before the release of the data that it is going to be a spectacular year for shareholders, which you will be able to find his interview in Youtube.
Why AML/MDS?
- The market is smaller and a better path from regulatory perspective because it would open opportunities other bigger market opportunities such as non-Hodgkin lymphoma. (see transcript). "if we can target those patients, we can take a story to the FDA, where we can attribute a very specific population that can be identified by very specific genetic mutations that are uniquely addressable with our drug. So that should lead to a very quick regulatory path. So that's the strategy. "
Technical Analysis:
I'm expecting some consolidation in the coming months at the $1.2X range. Then a pop to form a base at around $1.3-1.4 for NASDAQ listing compliance news to prevent reverse split.
I took a very small position as of today at $1.25.
